Looks like Samsung is looking to go against the grain and take some leverage from big pharma and give small biotechs like CYDY to not be forced into unfavorable deals (at least from a CMO perspective). Thanks for sharing!
Thank you for sharing. This is, by far, the best piece of empirical info to date! Sounds like this is a non-dilutive, guaranteed piece of financing!!
Kudos to whoever led negotiations for CYDY and Samsung for “thinking outside the box”. If this info can be spread and have CYDY named as the company, this can really move the needle. Odd that the article wouldn’t say who the company is.
I’d assume that Samsung has the right of first refusal to purchase or match the highest bid that CYDY gets, which could potentially lead to a bidding war.
News 
Market Data 
Discover 
AI
